CytoAgents, Inc

The "Cytokine Storm" is a term used to describe Cytokine Release Syndrome (CRS), which is a dangerous and potentially life-threatening overreaction of the immune system. CRS can be triggered by a wide range of indications, including viral and bacterial infections, autoimmune disorders, traumatic brain injury, and modern immunotherapies such as CAR T-cell therapy. Learn about CRS and how CytoAgents is leading the charge to develop a safe and effective solution: https://lnkd.in/eyd7hsFe #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

As researchers continue to seek new ways to expand the use of CAR T-cell therapy in oncology, it is equally important to focus on improving safety for patients who undergo this treatment. More than two-thirds of CAR T-cell therapy patients experience a potentially life-threatening side effect known as Cytokine Release Syndrome (CRS), which is an overreaction of the immune system. CytoAgents is developing an effective treatment for CRS, which will make CAR T-cell therapy safer for patients. Learn about it here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

CytoAgents' CEO Teresa Whalen, RPh, is optimistic about the future impact of her company's drug candidate, CTO1681, for the prevention and treatment of Cytokine Release Syndrome (CRS), a dangerous overreaction of the immune system. She commented: “We are thrilled to advance CTO1681 into the clinic to establish key insights into the safety and efficacy of our novel therapeutic ... Dosing our first patients in the lymphoma population is an important step forward for the company and the patients who may benefit.” Learn more about CRS and CTO1681 here: https://cytoagents.com/ #biotechleadership #biotech #healthcareleadership #biotechnology

The NF-kB pathway plays a critical role in the body’s natural regulation, activation, and differentiation of inflammatory T-cells. Excessive NF-kB actively results in pro-inflammatory cytokine amplification, as seen within Cytokine Release Syndrome (CRS), which contributes to the pathogenic processes of various inflammatory diseases. CytoAgents’ drug candidate, CTO1681, prevents and treats CRS by targeting the NF-kB signaling pathway via the activation of the EP4 receptor, which reduces NF-kB signaling, but does not shut it down completely. This, in turn, modulates cytokine production, resulting in reduced inflammation, while still allowing for a functioning immune system. Learn more about CRS and CTO1681 here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines Teresa Whalen, RPh

In the article below, the American Cancer Society describes chimeric antigen receptor (CAR) T-cell therapy as: "...a way to get immune cells called?T cells?(a type of white blood cell)?to fight cancer by changing them in the lab so they can find and destroy cancer cells." This revolutionary approach has helped to significantly improve patient outcomes. The article also discusses dangerous side effects to CAR T-cell therapy, including an overreaction of the immune system, known as Cytokine Release Syndrome (CRS). CytoAgents is developing an effective treatment to CRS, which will make CAR T-cell therapy safer for patients. Learn more here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

Thanks to the leadership of Teresa Whalen, RPh and her team of world-renowned clinical drug development experts and scientific advisory board members, CytoAgents has made tremendous strides in its mission to find a safe and effective treatment for Cytokine Release Syndrome (CRS), a dangerous overreaction of the immune system. Learn more about our mission, progress, and science here: https://cytoagents.com/ #biotechnology #biotech #leadership #healthcareleadership #crs

CytoAgents is a clinical-state biotech company focused on the development of innovative treatments for Cytokine Release Syndrome (CRS), a potentially life-threatening overreaction of the immune system. Our lead drug candidate, CTO1681, is an orally bioavailable, steroid-sparing immunomodulator for multiple CRS-inducing cytokines. Join us as we create a safe and effective solution that will improve patient outcomes and expand access to important treatment modalities. Get in touch here: https://lnkd.in/ex5wX5a8 #cytokinereleasesundrome #crs #cytokines #investors Teresa Whalen, RPh

While scientists continue to focus on improving chimeric antigen receptor (CAR) T-cell therapy in oncology, there needs to be a strong focus on patient safety. CytoAgents is developing a treatment for a common and potentially life-threatening side effect of CAR T-cell therapy known as Cytokine Release Syndrome (CRS), often referred to as the cytokine storm. Learn about CRS and CytoAgents' solution here: https://lnkd.in/eyd7hsFe #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

CytoAgents is focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS). At the helm is CEO Teresa Whalen, RPh, a biotech innovator, life sciences investor, and clinical pharmacist with a successful track record of bringing life-changing healthcare products to market. She leads a team of world-renowned clinical drug development experts and scientific advisory board members. Meet the CytoAgents team here: https://lnkd.in/g7P29x3i #biotechnology #biotech #healthcareleadership #leadership #crs

Cytokine Release Syndrome (CRS) is an overreaction of the immune system caused by excessive, prolonged cytokine production. CRS can be triggered by a wide range of indications, including modern immunotherapies such as CAR T-cell therapy. CytoAgents’ approach to treating CRS focuses on rebalancing the immune system by reducing the destructive impact of excessive cytokines while leaving necessary immune functions intact. Learn more here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh